Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase.

Ítems similars

• Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase.
  per: Keulen, W, et al.
  Publicat: (1997)
• Differential Removal of Thymidine Nucleotide Analogues from Blocked DNA Chains by Human Immunodeficiency Virus Reverse Transcriptase in the Presence of Physiological Concentrations of 2′-Deoxynucleoside Triphosphates
  per: Meyer, Peter R., et al.
  Publicat: (2000)
• Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase.
  per: Oude Essink, B B, et al.
  Publicat: (1997)
• Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV‐1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine
  per: Bertoletti, Nicole, et al.
  Publicat: (2019)
• Deoxynucleoside Triphosphate Incorporation Mechanism of Foamy Virus (FV) Reverse Transcriptase: Implications for Cell Tropism of FV
  per: Santos-Velazquez, Jose, et al.
  Publicat: (2008)